Vianna AGD, et al. - Authors explored the existence of a variation between the effects of vildagliptin and gliclazide modified release (MR) on glycemic variability (GV) in women with type 2 diabetes (T2DM) on steady-dose metformin monotherapy aged 61.9 ± 5.9 years, through continuous glucose monitoring (CGM). Findings disclosed that the difference between the groups did not reach statistical significance. It was inferred that vildagliptin and gliclazide MR similarly reduced the MAGE in women with T2DM following 24 weeks of therapy.